Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...

Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...

Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...

Every year, millions of newborns undergo routine screening as a preventive strategy to detect inherited disorders before symptoms emerge. Newborn screening (NBS) programs have traditionally relied on ...

Advances in genomics research and increasing adoption of high-throughput sequencing technologies are driving the demand for ...

Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the ...

Josh Lauer explores the trends shaping sequencing, the science behind SBX technology, and how AXELIOS 1 is designed to ...

Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the ...